References
- Hollowell J G, van Assendelft O W, Gunter E W, Lewis B G, Najjar M, Pfeiffer C. Hematological and iron-related analytes – reference data for persons aged 1 year and over: United States, 1988–94. Vital Health Stat 2005; 11: 1–156
- Tefferi A, Vardiman J W. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008; 22: 14–22
- Tefferi A, Pardanani A. Evaluation of “increased” hemoglobin in the JAK2 mutations era: a diagnostic algorithm based on genetic tests. Mayo Clin Proc 2007; 82: 599–604
- Pardanani A, Lasho T L, Finke C, Hanson C A, Tefferi A. Prevalence and clinicopathologic correlates of JAK2 exon 12 mutations in JAK2V617F-negative polycythemia vera. Leukemia 2007; 21: 1960–1963
- Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007; 110: 1092–1097
- Kondo T, et al. Validation of the revised 2008 WHO diagnostic criteria in 75 suspected cases of myeloproliferative neoplasm. Leuk Lymphoma 2008, in press
- Tefferi A. JAK and MPL mutations in myeloid malignancies. Leuk Lymphoma 2008; 49: 388–397